Home / Products
PS Chemical Consortium are proud to offer the highest quality semaglutide raw materials, essential for producing the groundbreaking medication developed by Novo Nordisk for treating type 2 diabetes in adults. Semaglutide has garnered global acclaim not only for its efficacy in blood sugar control but also for its remarkable potential in weight management and the promising prospects it shows in slowing cognitive decline associated with Alzheimer's disease.
As of the end of 2023, we have completed the construction of our semaglutide raw material production plant, capable of producing 300 kilograms annually. Our proprietary production process developed in-house, leverages solid-phase synthesis technology and incorporates a multifunctional peptide production line expected to be operational by the third quarter of this year. Additionally, a new peptide workshop is currently in the design phase, ensuring ongoing expansion of our production capabilities.
PS Chemical Consortium employs two primary synthesis methods for semaglutide production: chemical synthesis and synthetic biology fermentation. The latter includes yeast and E. coli fermentation, both of which we have extensively researched and developed.
PS Chemical Consortium is dedicated to driving innovation in the pharmaceutical industry. Our cutting-edge synthetic biology platform, supported by a robust strain library and high-throughput cell screening technologies, has established an industry-leading microbial expression system, ensuring top-tier fermentation yields. Our relentless pursuit of new drug types and synthesis processes exemplifies our commitment to technological advancement.
Unlike chemical synthesis, synthetic biology fermentation is not constrained by scale, allowing us to meet large-scale production requirements.
Synthetic biology methods offer significant cost advantages, especially in the production of solid dosage forms.
PS Chemical Consortium has first-class factories and production lines that can ensure stable production capacity.
